October 2015, Vol. 4, No. 5
Immunotherapy Will Alter the NSCLC Treatment Landscape16th International Lung Cancer Congress
Despite the promise of molecular profiling, approximately 80% of patients with lung cancer lack a defined genotypic mutation and thus become resistant when treated with a tyrosine kinase inhibitor. According to data presented at the congress, however, lung cancer remains a highly mutated disease, suggesting great potential for immunotherapy.
âIf you look at lung cancers and the number of mutations per megabase of DNA, theyâre right up here,â said Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research, Yale Comprehensive Cancer Center, New Haven, CT. âLung and bladder and small cell and nonâsmall cell lung cancers alike are highly mutated, so youâd think that the immune system could recognize some of the neoantigens.â
As Herbst explained, specificity, memory, and adaptability are the key attributes of the immune system that make it such a promising weapon of defense. Cancer cells develop many mutations that can make them appear foreign to the immune system. The problem is, however, that these cells can also exploit immune checkpointsâturning off these molecules to stop the immune responseâand evade detection.
âThe job of cancer immunotherapies,â said Herbst, âis to relieve this block and make the tumor visible to the immune system again….And if we can prime the immune system the right way to recognize cancer, this immunity should have durability.â
Smokers Respond Better
Although immunotherapy has been used successfully in the treatment of certain lung cancers, it is not for every patient. For example, most patients with squamous cell carcinoma have been smokers, said Herbst, so they have a higher number of mutations. Nivolumab has been used effectively in the second-line setting in these patients, with improvements seen in survival. In nonsquamous cell carcinoma, however, the benefits are less pronounced.
âWe have therapies that are working,â said Herbst, âbut using biomarkers will help us find patients who are going to benefit more, so they can get these drugs early on. If the patient isnât benefitting, he or she can receive combination therapies and other approaches.â
âThose who are smokers, who have more mutations, tend to do a little better with these therapies,â he added. âAlthough, what is the right end point? Is it response or survival? We still need to figure that out.â
The trick, Herbst elaborated, is to identify those patients who are alive at 1 or 2 years and determine who they are at the beginning of treatment.
Although the survival benefit of these therapies for certain populations has been great, Herbst cautioned that these agents are ânot a free ride.â For example, in diseases of the endocrine gland, such as hypothyroidism, these therapies often carry irreversible side effects, even when patients are treated with steroids.
âIf it says âitisâ on it, you can get it,â he said. âI would think these toxicities are more manageable than cytotoxic chemotherapy, but they can still be pretty serious. Physicians have to look for them.â
Much of immunotherapy research is therefore centered on acceptable toxicityâfiguring out ways to produce better responses and activity early on by combining the right drugs. The ultimate aim is to increase the number of patients who can experience long-term survival.
Herbst and his team at Yale have been very focused on rebiopsies at multiple points throughout the patientâs treatment.
âWhen you look at a rebiopsy, you see distorted immune cells and fragments of tumor cells, but you really donât see any viable tumors,â he said. âThatâs very reassuring, but we want to do more and determine the molecular characteristics of an inactive immune response.â
Challenges notwithstanding, the results of immunotherapy have been extraordinary, Herbst concluded. âI believe that science will drive the day with these agents.â
Biomarkers have a promising role in the early detection and risk stratification of colonic neoplasia, lung cancer, and breast cancer said presenters at PMO Live 2015. Molecular Biomarkers: Colorectal Cancer The vast majority of screening colonoscopies are negative for significant lesions of advanced adenomas or carcinoma in average-risk and even [ Read More ]
Dear Colleague, I am pleased to announce a new department in PMO, Genetic Counseling. In each issue, PMO editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center will contribute an impactful article. In this issue, you will read about BRCA1/2 testing for any patient with pancreatic adenocarcinoma. [ Read More ]